BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7829269)

  • 21. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
    Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
    Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
    Xiang J; Sha Y; Jia Z; Prasad L; Delbaere LT
    J Mol Biol; 1995 Oct; 253(3):385-90. PubMed ID: 7473721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
    Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
    Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer.
    Bulens F; Vandamme AM; Bernar H; Nelles L; Lijnen RH; Collen D
    Eur J Biochem; 1991 Jan; 195(1):235-42. PubMed ID: 1899382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
    Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
    J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen.
    Caldas C; Coelho V; Kalil J; Moro AM; Maranhão AQ; Brígido MM
    Mol Immunol; 2003 May; 39(15):941-52. PubMed ID: 12695120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-specific modifications of light chain glycosylated antilymphoma (LL2) and anti-carcinoembryonic antigen (hImmu-14-N) antibody divalent f1agments.
    Govindan SV; Goldenberg DM; Griffiths GL; Leung SO; Losman MJ; Hansen HJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5721s-5725s. PubMed ID: 7493334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
    Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
    Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells.
    Shlomchik MJ; Nemazee DA; Sato VL; Van Snick J; Carson DA; Weigert MG
    J Exp Med; 1986 Aug; 164(2):407-27. PubMed ID: 3088205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab.
    Rosok MJ; Yelton DE; Harris LJ; Bajorath J; Hellström KE; Hellström I; Cruz GA; Kristensson K; Lin H; Huse WD; Glaser SM
    J Biol Chem; 1996 Sep; 271(37):22611-8. PubMed ID: 8798431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
    Batra SK; Niswonger ML; Wikstrand CJ; Pegram CN; Zalutsky MR; Morrison SL; Bigner DD
    Hybridoma; 1994 Apr; 13(2):87-97. PubMed ID: 8050781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody.
    Arakawa F; Kuroki M; Kuwahara M; Senba T; Ozaki H; Matsuoka Y; Misumi Y; Kanda H; Watanabe T
    J Biochem; 1996 Sep; 120(3):657-62. PubMed ID: 8902633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
    Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
    Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
    Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
    Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutamine-linked and non-consensus asparagine-linked oligosaccharides present in human recombinant antibodies define novel protein glycosylation motifs.
    Valliere-Douglass JF; Eakin CM; Wallace A; Ketchem RR; Wang W; Treuheit MJ; Balland A
    J Biol Chem; 2010 May; 285(21):16012-22. PubMed ID: 20233717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumour activity of a chimeric antibody against the leucocyte antigen CD48.
    Sun H; Biggs JC; Smith GM
    Cancer Immunol Immunother; 2000 Jan; 48(10):595-602. PubMed ID: 10630312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2.
    Shih LB; Lu HH; Xuan H; Goldenberg DM
    Int J Cancer; 1994 Feb; 56(4):538-45. PubMed ID: 8112889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs.
    Lund J; Takahashi N; Nakagawa H; Goodall M; Bentley T; Hindley SA; Tyler R; Jefferis R
    Mol Immunol; 1993 Jun; 30(8):741-8. PubMed ID: 8502242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
    Hand PH; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri SV
    Cancer Immunol Immunother; 1992; 35(3):165-74. PubMed ID: 1638552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.